Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof
The induction of indoleamine 2,3-dioxygenase (IDO) in an IDO-competent subset of dendritic cells by TLR ligands, including TLR9 ligands, and various uses thereof are presented.
1 . A method of enhancing an immune response in a subject, the method comprising administering to the subject a TLR9 agonist and an inhibitor of IDO.
2 . The method of claim 1 , the method further comprising administering to the subject an antigen and wherein the immune response to the antigen in the subject is enhanced.
3 . The method of claim 1 , wherein CD8 T cell activation in the subject is stimulated.
4 . A method of treating cancer in a subject, the method comprising administering to the subject a TLR9 agonist, an inhibitor of IDO, and an additional antineoplastic therapeutic agent.
5 . The method of claim 6 , wherein a T cell mediated immune response in the subject is suppressed.
6 . A method of inducing indoleamine 2,3-dioxygenase (IDO) expression in dendritic cells in a subject, the method comprising administering to the subject a TLR9 agonist in an amount effective to induce IDO expression in a subset of dendritic cells.
7 . (canceled)
8 . A method of suppressing T cell activation to an antigen in a subject, the method comprising administering to the subject a TLR9 agonist and the antigen, wherein the TLR9 agonist is administered in an amount effective to induce IDO expression in a subset of dendritic cells.
9 . The method of claim 8 wherein the TLR9 agonist and the antigen are administered simultaneously.
10 . The method of claim 8 wherein the TLR9 agonist is administered prior to the administration of the antigen.
11 . The method of claim 8 , wherein the antigen is an alloantigen.
12 . A method of inducing tolerance to an antigen in a subject, the method comprising administering to the subject a TLR9 agonist and the antigen, wherein the TLR9 agonist is administered in an amount effective to induce IDO expression in a subset of dendritic cells.
13 . A method of preventing allograft rejection in a subject, the method comprising administering to the subject a TLR9 agonist and one or more alloantigens present in the allograft.
14 . The method of claim 13 wherein the TLR9 agonist is administered to the recipient after the transplantation of the allograft into the recipient.
15 . A method of preventing graft versus host disease in a recipient, the method comprising:
administering to the donor a TLR9 agonist and one or more alloantigens present in the recipient, wherein the TLR9 agonist and the one or more alloantigens present in the recipient are administered to the donor prior to obtaining donor cells from the donor;
obtaining donor cells from the donor; and
administering the donor cells to the recipient.
16 . A method of preconditioning a recipient of an allograft to suppress allograft rejection in the recipient, the method comprising:
administering to the recipient a TLR9 agonist and one or more alloantigens present in the allograft, wherein the TLR9 agonist and the one or more alloantigens present in the allograft are administered to the recipient prior to allografting; and
transplanting the allograft into the recipient.
17 . The composition of claim 18 , the composition further comprising an antigen.
18 . A composition comprising a TLR9 agonist and an inhibitor of IDO.
19 . An isolated cell population preconditioned to minimize graft versus host disease when transplanted into a donor recipient, the cell population obtained by a method comprising:
administering to the donor a TLR9 agonist and one or more alloantigens present in the recipient, wherein the TLR9 agonist and the one or more alloantigens present in the recipient are administered to the donor prior to obtaining donor cells from the donor; and
obtaining donor cells from the donor.
20 . The method of claim 1 , wherein the TLR9 agonist is a CpG-oligonucleotide
21 . The method of claim 1 , wherein the TLR9 agonist is administered systemically.